AU2002227240A1 - Treatment and method using loratadine and montelukast - Google Patents

Treatment and method using loratadine and montelukast

Info

Publication number
AU2002227240A1
AU2002227240A1 AU2002227240A AU2724002A AU2002227240A1 AU 2002227240 A1 AU2002227240 A1 AU 2002227240A1 AU 2002227240 A AU2002227240 A AU 2002227240A AU 2724002 A AU2724002 A AU 2724002A AU 2002227240 A1 AU2002227240 A1 AU 2002227240A1
Authority
AU
Australia
Prior art keywords
montelukast
loratadine
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002227240A
Inventor
Alan G. Harris
Paul T. Medeiros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2002227240A1 publication Critical patent/AU2002227240A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
AU2002227240A 2000-10-30 2001-10-26 Treatment and method using loratadine and montelukast Abandoned AU2002227240A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24422600P 2000-10-30 2000-10-30
US60/244,226 2000-10-30
PCT/US2001/046596 WO2002036124A2 (en) 2000-10-30 2001-10-26 Treatment and method using loratadine and montelukast

Publications (1)

Publication Number Publication Date
AU2002227240A1 true AU2002227240A1 (en) 2002-05-15

Family

ID=22921893

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002227240A Abandoned AU2002227240A1 (en) 2000-10-30 2001-10-26 Treatment and method using loratadine and montelukast

Country Status (3)

Country Link
US (5) US20020052388A1 (en)
AU (1) AU2002227240A1 (en)
WO (1) WO2002036124A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002256967A1 (en) * 2000-10-30 2002-09-12 Schering Corporation Treating or reducing the risk of cardiovascular disease
WO2003101434A2 (en) * 2001-12-21 2003-12-11 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
WO2005089761A1 (en) * 2004-03-17 2005-09-29 Pfizer Limited Combination for treating inflammatory diseases
WO2008079312A2 (en) * 2006-12-22 2008-07-03 Schering Corporation Compositions for treatment of nasal congestion
EP2121021A2 (en) * 2006-12-22 2009-11-25 Schering Corporation Methods for treating nasal congestion in hypertensive or diabetic patients
CA2704728A1 (en) * 2007-09-18 2009-03-26 Stephen Wills Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors
CN110496124A (en) * 2019-04-10 2019-11-26 中山大学附属第五医院 The compound for treating vascular malformation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177259A (en) * 1986-04-11 1993-01-05 Warner-Lambert Company Diarylalkanoids having activity as lipoxygenase inhibitors
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
NZ331160A (en) * 1996-02-08 2000-07-28 Merck & Co Inc use of loratadine and a leukotriene antagonist to treat asthma
US6599913B1 (en) * 2001-06-29 2003-07-29 Schering Corporation Treating allergic and inflammatory conditions

Also Published As

Publication number Publication date
US20080269273A1 (en) 2008-10-30
US20060270697A1 (en) 2006-11-30
WO2002036124A2 (en) 2002-05-10
WO2002036124A3 (en) 2003-02-13
US20020052388A1 (en) 2002-05-02
US20100160366A1 (en) 2010-06-24
US20040167150A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
AU2001286419A1 (en) Endourethral device and method
EP1361604A4 (en) Device and method for treatment
AU2898500A (en) Biosensor device and method
AU2001283546A1 (en) Inhalation device and method
AU2002227414A1 (en) Infusion devices and method
AU6416501A (en) Human interface method and apparatus
AU3309300A (en) Hair treatment device and method
AU2001292302A1 (en) Heat-treating apparatus and heat-treating method
AU2001257069A1 (en) Photostimulaton treatment apparatus and methods for use
AU2001232647A1 (en) Methods and devices for treating stuttering problems
AU2002245675A1 (en) Electromanipulation device and method
AU2001265967A1 (en) Cryptographic method and cryptographic device
AU2001214905A1 (en) Security device and method
AU2001274521A1 (en) Receiving device and receiving method
AU2002227240A1 (en) Treatment and method using loratadine and montelukast
AUPQ793100A0 (en) Improved chemical treatment methods and apparatus
AUPR222300A0 (en) Electrophoresis device and method
AU2001238090A1 (en) Heating method and device
AU2001235492A1 (en) Method and device for effluent treatment
AUPR496501A0 (en) Method and device
AU2001294232A1 (en) Content acquiring method and content acquiring device
AU2001292366A1 (en) Receiving device and receiving method
AU2002241525A1 (en) Cardiac deblocking device and method
AU2001260894A1 (en) Method and device
AU2001260161A1 (en) Pellet-freezing device and process